PestleMedicine Explained

Inclisiran

Leqvio is an injection containing inclisiran, which lowers LDL-cholesterol ("bad" cholesterol). It is used alongside a cholesterol-lowering diet in adults with a high blood cholesterol level (primary hypercholesterolaemia, including heterozygous familial and non-familial, or mixed dyslipidaemia).

Active ingredient: inclisiran

Official leaflet

Key facts

  1. Leqvio lowers LDL-cholesterol by limiting the production of a protein called PCSK9.
  2. It is given as an injection under the skin by a doctor, pharmacist or nurse: one dose, a second dose after 3 months, then a dose every 6 months.
  3. You should stay on your cholesterol-lowering diet and keep taking your statin all the time you receive Leqvio.
  4. It must not be given to children and adolescents under 18 years of age.
  5. If you miss your appointment, contact your doctor, pharmacist or nurse as soon as you can to arrange your next injection.

Who should not take inclisiran

The leaflet says not to take it if any of these apply to you.

  • If you are allergic to inclisiran or any of the other ingredients of this medicine

Check with a doctor or pharmacist first

Tell them before you take it if any of these apply to you.

  • If you are receiving dialysis
  • If you have severe liver disease
  • If you have severe kidney disease
  • Do not give to children and adolescents under 18 years of age, because there is no experience of using it in this age group

How to take inclisiran

  • The recommended dose is 284 mg given by injection under the skin (subcutaneous injection).
  • The next dose is given after 3 months, followed by further doses every 6 months.
  • It is given by a doctor, pharmacist or nurse into the abdomen; the upper arm or thigh may also be used.
  • Stay on your cholesterol-lowering diet and keep taking your statin while you receive Leqvio.
  • If you miss your appointment, contact your doctor, pharmacist or nurse as soon as you can to arrange your next injection.

Side effects

How common each side effect is

Grouped the way the leaflet groups them. Most people get none, or only a few. Each figure is the most that are affected, so "up to 1 in 10" can mean far fewer.

Common

Up to 1 in 10 people

  • Injection site reactions, such as pain, redness or rash

If you get a side effect, you can report it to the regulator through the Yellow Card scheme.

Pregnancy and breastfeeding

The use of Leqvio should be avoided during pregnancy. It is not known whether Leqvio passes into breast milk, so ask your doctor, pharmacist or nurse for advice before you are given it if you are pregnant, breast-feeding, think you may be pregnant or are planning a baby.

Taking it with other medicines

The leaflet says to tell your doctor or pharmacist if you take any of these. This list is not checked against the medicines you take.

  • Any other medicines you are using, have recently used or might use

Where this comes from

Everything on this page is taken from one official document: the patient information leaflet that the UK medicines regulator (MHRA) approved for this product. Pestle reorganises it and puts it in plainer words. It adds nothing from anywhere else and does not rate medicines.

Product
Leqvio 284 mg Solution For Injection In Prefilled Syringe
Product licence
PLPI163781372
Leaflet dated
Checked against the leaflet
Automated check
1 of 1 side effects matched to the wording of the leaflet

Other makers of inclisiran publish their own leaflets, which can differ slightly. Always read the leaflet that came with your medicine.

Read the official leaflet Original on the MHRA site How we make these pages

The same facts for software and AI agents: JSON · Markdown.